NMPA Publishes 110th Batch of Chemical Generic Drug Reference Listed Drug Catalog – 28 New Specifications Added
Policy / Regulatory

NMPA Publishes 110th Batch of Chemical Generic Drug Reference Listed Drug Catalog – 28 New Specifications Added

The National Medical Products Administration (NMPA) has released the 110th batch of the Catalog of Reference Listed Drugs (RLD) for Chemical Generic Drugs, adding 28 new drug specifications and providing…

FDA Approves AbbVie's Tavapadon as Juvmo for Parkinson's Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfoli
CompanyDrug

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

Jenscare's JensClip Wins NMPA Registration Approval – Self‑Locking Transcatheter Mitral Valve Repair Clip Enters the Chinese Market
CompanyMedical Device

Jenscare’s JensClip Wins NMPA Registration Approval – Self‑Locking Transcatheter Mitral Valve Repair Clip Enters the Chinese Market

Novo Nordisk's NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China
CompanyDrug

Novo Nordisk’s NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China

Merck's Subcutaneous Pembrolizumab Approved by China's NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China
CompanyDrug

Merck’s Subcutaneous Pembrolizumab Approved by China’s NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World's First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma
CompanyDrug

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World’s First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma

European Commission Approves Novartis' Cosentyx for Polymyalgia Rheumatica – First and Only IL-17A Inhibitor for Adult PMR in Europe
CompanyDrug

European Commission Approves Novartis’ Cosentyx for Polymyalgia Rheumatica – First and Only IL-17A Inhibitor for Adult PMR in Europe

LongBio Pharma Reports Positive Top-Line Phase II Data for LP-005 – Bifunctional C5/C3b Antibody Achieves 100% Hemolysis Control in PNH
CompanyDrug

LongBio Pharma Reports Positive Top-Line Phase II Data for LP-005 – Bifunctional C5/C3b Antibody Achieves 100% Hemolysis Control in PNH

European Commission Approves Merck's KEYTRUDA Plus Padcev for Resectable Muscle-Invasive Bladder Cancer – First and Only PD-1 Inhibitor–ADC Regimen for MIBC in the EU
CompanyDrug

European Commission Approves Merck’s KEYTRUDA Plus Padcev for Resectable Muscle-Invasive Bladder Cancer – First and Only PD-1 Inhibitor–ADC Regimen for MIBC in the EU

Biostar's Oral Utidelone Capsule Achieves First Patient Dosing in Phase 3 – Non‑Inferiority Bridging Study vs. Marketed Utidelone Injection in HER2‑Negative Advanced Breast Cancer
CompanyDrug

Biostar’s Oral Utidelone Capsule Achieves First Patient Dosing in Phase 3 – Non‑Inferiority Bridging Study vs. Marketed Utidelone Injection in HER2‑Negative Advanced Breast Cancer

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib

GlaxoSmithKline Plc (GSK; NYSE: GSK) announced the first global data for risvutatug rezetecan (Ris‑Rez, HS‑20093), its investigational B7‑H3‑targeted antibody‑drug conjugate (ADC), in patients with relapsed extensive‑stage small cell lung cancer (ES‑SCLC). Results from the Phase Ib dose‑optimization portion of the…

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Roche Reports 9M 2026 Sales of CHF 46.493 Billion, Up 6% at CER – Ocrevus Leads as Pharmaceuticals Division Drives Growth and Full-Year Guidance Is Confirmed
Company

Roche Reports 9M 2026 Sales of CHF 46.493 Billion, Up 6% at CER – Ocrevus Leads as Pharmaceuticals Division Drives Growth and Full-Year Guidance Is Confirmed

Siemens Healthineers and NVIDIA Partner to Develop Next-Generation Adaptive Radiotherapy Technology – Combining Agentic and Robotic Intelligence With Accelerated Computing
CompanyDeals

Siemens Healthineers and NVIDIA Partner to Develop Next-Generation Adaptive Radiotherapy Technology – Combining Agentic and Robotic Intelligence With Accelerated Computing

Reju Therapeutics Completes Oversubscribed Series A Financing of Hundreds of Millions of RMB – China's First Senotherapeutics Biotech Backed by Top-Tier Investors
CompanyDeals

Reju Therapeutics Completes Oversubscribed Series A Financing of Hundreds of Millions of RMB – China’s First Senotherapeutics Biotech Backed by Top-Tier Investors

Abbott to Separate Nutrition Business Into Independent Public Company – USD 8.5 Billion Global Leader in Healthy Nutrition
Company

Abbott to Separate Nutrition Business Into Independent Public Company – USD 8.5 Billion Global Leader in Healthy Nutrition

OrbusNeich Completes Acquisition of Italian Distributor MC Health – 100% Equity Deal Shifts Italy Operations to Direct Sales Model for Coronary Portfolio
CompanyDeals

OrbusNeich Completes Acquisition of Italian Distributor MC Health – 100% Equity Deal Shifts Italy Operations to Direct Sales Model for Coronary Portfolio

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
HutchMed Completes USD 1.295 Billion Licensing Transaction with GSK for HMPL‑A830 – First‑in‑Class KRAS‑Inhibitor ATTC Targets EGFR‑Expressing Tumors Globally
CompanyDeals

HutchMed Completes USD 1.295 Billion Licensing Transaction with GSK for HMPL‑A830 – First‑in‑Class KRAS‑Inhibitor ATTC Targets EGFR‑Expressing Tumors Globally

HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced the completion of the transaction under its exclusive development and license agreement with GlaxoSmithKline ("GSK"), granting a subsidiary of GSK the exclusive…

Alcon Acquires Neurotech Pharmaceuticals for USD 550 Million – Deal Brings ENCELTO, First FDA‑Approved MacTel Type 2 Therapy, Into Retina Portfolio
CompanyDeals

Alcon Acquires Neurotech Pharmaceuticals for USD 550 Million – Deal Brings ENCELTO, First FDA‑Approved MacTel Type 2 Therapy, Into Retina Portfolio

Cutia Therapeutics Expands CU-20401 Licensing Collaboration with Rejuven Dermaceutical Beyond Asia – Recombinant Mutant Collagenase for Localized Fat Reduction Goes Global
CompanyDeals

Cutia Therapeutics Expands CU-20401 Licensing Collaboration with Rejuven Dermaceutical Beyond Asia – Recombinant Mutant Collagenase for Localized Fat Reduction Goes Global

Zelgen Receives USD 10 Million Milestone Payment from AbbVie for ZG006 (Alveltamig) – Clinical Progress Triggers Second Payout Under Global Oncology Collaboration
CompanyDeals

Zelgen Receives USD 10 Million Milestone Payment from AbbVie for ZG006 (Alveltamig) – Clinical Progress Triggers Second Payout Under Global Oncology Collaboration

METiS TechBio Partners with Eli Lilly on AI‑Driven Lipid Nanoparticle Delivery – Up to USD 1.1 Billion in Milestones for Tissue‑Specific LNP Discovery
CompanyDeals

METiS TechBio Partners with Eli Lilly on AI‑Driven Lipid Nanoparticle Delivery – Up to USD 1.1 Billion in Milestones for Tissue‑Specific LNP Discovery

- Advertisement -
Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares
CompanyDeals

Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1
CompanyDeals

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech's CNS and Brain‑Penetrant Drug Pipeline
CompanyDeals

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech’s CNS and Brain‑Penetrant Drug Pipeline

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances "Closed‑Loop Nerve Bundle Modulation" Platform
CompanyDeals

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances “Closed‑Loop Nerve Bundle Modulation” Platform

China's CDE Launches "Pioneer Plan" Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing
Policy / Regulatory

China’s CDE Launches “Pioneer Plan” Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing

The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) issued the Pilot Plan for Promoting the Research and Application of New Approach Methodologies (the "Pioneer Plan"),…

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs
Policy / Regulatory

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition
Policy / Regulatory

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition

CDE Opens Public Comment on 111th Batch Draft of Reference Preparations Catalogue – 25 New Specifications Proposed for Chemical Generic Drugs
Policy / Regulatory

CDE Opens Public Comment on 111th Batch Draft of Reference Preparations Catalogue – 25 New Specifications Proposed for Chemical Generic Drugs

More News

CompanyDrug

Bao Pharmaceuticals’ BJ045 Wins NMPA Clinical Trial Approval – Enzyme‑Resistant Subcutaneous Anti‑CD20 Antibody Engineered for Combination With IgG‑Degrading KJ103

Sanofi and Teva Present 44‑Week RELIEVE UCCD Extension Data – TL1A Antibody Duvakitug Sustains Efficacy Across Ulcerative Colitis and Crohn's Disease Endpoints
CompanyDrug

Sanofi and Teva Present 44‑Week RELIEVE UCCD Extension Data – TL1A Antibody Duvakitug Sustains Efficacy Across Ulcerative Colitis and Crohn’s Disease Endpoints

Sino Biopharmaceutical Completes Phase III Enrollment for TQC2731 – Upstream TSLP Antibody Targets Maintenance Treatment of Chronic Rhinosinusitis With Nasal Polyps
CompanyDrug

Sino Biopharmaceutical Completes Phase III Enrollment for TQC2731 – Upstream TSLP Antibody Targets Maintenance Treatment of Chronic Rhinosinusitis With Nasal Polyps

Takeda's VERDICT Study: ENTYVIO‑Driven Disease Clearance Cuts Ulcerative Colitis Complication Risk by Nearly 70% – First Randomized Evidence for a Treat‑to‑Target Paradigm
CompanyDrug

Takeda’s VERDICT Study: ENTYVIO‑Driven Disease Clearance Cuts Ulcerative Colitis Complication Risk by Nearly 70% – First Randomized Evidence for a Treat‑to‑Target Paradigm

Leads Biolabs' Opamtistomig Shows Positive Phase 2 Efficacy Signals in First‑Line Gastric Cancer – Anti‑PD‑L1/4‑1BB Bispecific Advances to Expansion Stage
CompanyDrug

Leads Biolabs’ Opamtistomig Shows Positive Phase 2 Efficacy Signals in First‑Line Gastric Cancer – Anti‑PD‑L1/4‑1BB Bispecific Advances to Expansion Stage

Ascentage Pharma's Lisaftoclax Wins CDE Breakthrough Therapy Designation – Bcl‑2 Inhibitor Plus Acalabrutinib Tapped for First‑Line CLL/SLL
CompanyDrug

Ascentage Pharma’s Lisaftoclax Wins CDE Breakthrough Therapy Designation – Bcl‑2 Inhibitor Plus Acalabrutinib Tapped for First‑Line CLL/SLL

GSK Wins FDA Approval for Hibsago (bepirovirsen) – First‑in‑Class Antisense Oligonucleotide Delivers Functional Cure Potential in Chronic Hepatitis B
CompanyDrug

GSK Wins FDA Approval for Hibsago (bepirovirsen) – First‑in‑Class Antisense Oligonucleotide Delivers Functional Cure Potential in Chronic Hepatitis B

Sihuan Pharmaceutical's PCL Facial Filler and L‑Carnosine Skin Booster Win Hong Kong Market Approval – Meiyan Space Aesthetics Duo Expands Beyond Mainland China
CompanyDrug

Sihuan Pharmaceutical’s PCL Facial Filler and L‑Carnosine Skin Booster Win Hong Kong Market Approval – Meiyan Space Aesthetics Duo Expands Beyond Mainland China

Show More